Sign In
Buy TMDX
$76.51
+0.380 (+0.499%)
At Close: Jul 31, 2026
TransMedics (TMDX) Crossed Above the 50-Day Moving Average: What That Means for Investors
10:35am, Thursday, 20'th Nov 2025
TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 50-day moving average, which suggests a sh
TransMedics (TMDX) Just Overtook the 20-Day Moving Average
10:35am, Thursday, 20'th Nov 2025
From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 20-day moving average, and this suggests a s
TransMedics (TMDX) is a Top-Ranked Growth Stock: Should You Buy?
10:45am, Wednesday, 19'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
04:05pm, Tuesday, 18'th Nov 2025
ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
Envestnet Asset Management Inc. Buys 2,933 Shares of TransMedics Group, Inc. $TMDX
04:23am, Sunday, 16'th Nov 2025
Envestnet Asset Management Inc. lifted its stake in TransMedics Group, Inc. (NASDAQ: TMDX) by 12.6% during the undefined quarter, according to the company in its most recent disclosure with the Securi
Polen U.S. Small Cap Growth Q3 2025 Portfolio Performance And Attribution
03:50am, Thursday, 06'th Nov 2025
During the third quarter of 2025, the U.S. Small Cap Growth Composite Portfolio returned 21.4% gross and 21.1% net of fees. Bloom Energy is a provider of solid oxide fuel cells that play a critical ro
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 31'st Oct 2025
ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics: Growth Tailwinds Should Provide Upside In 2026
11:54am, Friday, 31'st Oct 2025
TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on
TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
03:01pm, Thursday, 30'th Oct 2025
TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.
TransMedics: Q3 Results Disappointed, As Expected (Rating Upgrade)
11:23am, Thursday, 30'th Oct 2025
TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuat
TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript
10:56pm, Wednesday, 29'th Oct 2025
TransMedics Group, Inc. ( TMDX ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Confe
TransMedics (TMDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
08:31pm, Wednesday, 29'th Oct 2025
Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall
TransMedics (TMDX) Beats Q3 Earnings Estimates
06:36pm, Wednesday, 29'th Oct 2025
TransMedics (TMDX) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.12 per share a year ago.
TransMedics Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 29'th Oct 2025
ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
Heart Transplant Play Nears Buy Point. Analysts See Earnings Surging Again.
01:17pm, Tuesday, 28'th Oct 2025
TransMedics is rising in a 20-weeks-long consolidation that has a buy point of 145.50.
